Comparative Pharmacology
Head-to-head clinical analysis: EPINEPHRINE BITARTRATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINEPHRINE BITARTRATE IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Alpha-adrenergic effects increase peripheral vascular resistance and blood pressure. Beta1-adrenergic effects increase heart rate and contractility. Beta2-adrenergic effects cause bronchodilation and vasodilation in skeletal muscle.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion: 0.1 to 1 mcg/kg/min, titrated to effect. Intravenous bolus: 1 mg every 3-5 minutes as needed for cardiac arrest. Intramuscular: 0.3 to 0.5 mg (1:1000 solution) for anaphylaxis, repeat every 5-15 minutes if necessary.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life: ~2 minutes following intravenous administration; clinical context: ultrashort duration necessitates continuous infusion or repeated boluses for sustained effect.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily renal; 90% as metabolites (metanephrine, vanillylmandelic acid) and unchanged drug; biliary/fecal <5%.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte